Myo-inositol; an identified biomarkerthrough metabolomics approaches in thyroid lesions

Background: Metabolomics is the study of small molecules,called metabolites, in various biological specimens. Metaboliteprofiling, which is also commonly referred to, is a relativelyrecent addition to the fields of system biology and OMICS. Metabolitesare the end product of genes, transcripts, and proteinsactivity, and their concentrations can be served as a sensitivebiomarker of different diseases. Myo-inositol (MI) is a metabolitethat has gained attention in recent times for its potential indiagnosis, prognosis, and treating a range of diseases, includingcancer. In this study, the role of MI in thyroid lesions has beeninvestigated.Materials and Methods: A literature search was carried outon Google Scholar and PubMed, then high quality articles in awide time-frame from ۲۰۰۰ to ۲۰۲۳ were reviewed.Results: MI is the most common isomer of inositol family, a cyclicpolyol with ۶ hydroxyl groups. MI is obtained both throughendogenous biosynthesis and dietary intake. MI plays importantroles in various physiological functions, including osmoticregulation, cell membrane synthesis, hormone signaling pathways(such as insulin, thyrotropin-releasing hormone, thyroidstimulating hormone (TSH), follicle-stimulating hormone) andneurotransmitter messenger pathways. As a second messengerin the TSH signaling pathway, MI can organize the formationof hydrogen peroxide in thyroid cells. It plays a vital role in theprocess of iodination of thyroglobulin and synthesis of thyroidhormones. Decreased MI is associated with impaired TSH productionand thyroid diseases, including hypothyroidism, autoimmunethyroiditis, and thyroid cancer. Clinical studies haveshown that MI supplementation has an effect on maintainingthe triiodothyronine: thyroxine ratio, reducing anti-thyroid autoantibodies,and the volume of thyroid nodules.Conclusion: This review suggests the potential therapeutic applicationsof MI in the treatment of thyroid lesions, especiallythyroid cancer.

کلیدواژه ها:

Biomarker ، Metabolomics ، Myo-inositol ، Thyroidcancer